News

May 15 2025

Tevard Reports Data on Suppressor tRNA Therapy Restoring Full-Length Dystrophin in Duchenne Muscular Dystrophy Model

Read more
Apr 29 2025

Tevard to Present Data Demonstrating tRNA-based Therapy Rescued Full-Length Dystrophin and Motor Function in Duchenne Muscular Dystrophy Model

Read more
Aug 13 2024

Tevard Biosciences to Move Corporate Headquarters to Lilly Gateway Labs in Boston’s Seaport

Read more
Jun 24 2024

Industry Veteran and RNA Therapeutics Expert, John Maraganore, Joins Tevard Biosciences as Strategic Advisor and Board Observer

Read more
Nov 13 2023

Tevard Biosciences appoints Dr. Gregory Robinson as Chief Scientific Officer

Read more
Feb 28 2023

Tevard Biosciences announces collaboration with Vertex to develop novel tRNA-based therapies for Duchenne muscular dystrophy

Read more
Aug 03 2022

Tevard Biosciences Appoints Zoya Ignatova to Its Scientific Advisory Board

Read more
Apr 26 2022

Tevard CEO Awarded Henri Termeer Fellowship

Read more
Mar 31 2022

Tevard Biosciences licenses mRNA Amplifier technology from Johns Hopkins University

Read more
Mar 09 2022

Tevard Biosciences Appoints Paul Schimmel, Susan Ackerman, and Nicholas Ingolia to Its Scientific Advisory Board

Read more